Compare Charles Schwab Corporation Common Stock (SCHW) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Tempus AI — how do they compare? Charles Schwab Corporation Common Stock trades at $97 (market cap $165.29B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 12.9× Tempus AI's market cap, and Charles Schwab Corporation Common Stock pays a 1.34% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and Tempus AI for 22 Days on average.
| SCHW | TEM | |
|---|---|---|
Market Cap | $165.29B | $12.77B |
Volume | 7,114,246 | 8,980,490 |
Sector | Financials | Broad Market / Factor |
52-Week High | $113.65 | $99.28 |
52-Week Low | $85.35 | $41.55 |
Typical Hold Time | 85 Days | 22 Days |
Enterprise Value | $151.73B | $13.40B |
Dividend Yield | 1.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.87, up 0.07% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.62 exceeding expectations of $1.56. Revenue grew to $23.92B in 2025 with 37% profit margin, while analyst consensus remains bullish with a $119.92 price target. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships.
SCHW presents a compelling value opportunity with attractive valuation metrics (P/E 17.41) and strong profitability (ROE 22.45%). Near-term risks include technical bearish momentum and market volatility, but long-term growth prospects in the expanding e-brokerage market and operational efficiency gains support upside potential to analyst targets.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
